Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy

HER2-targeted therapy is currently the subject of several studies in lung cancer and other solid tumors using either tyrosine kinase inhibitors (TKI) or targeted-antibody–drug conjugates. We describe a 61-year-old female patient with HER2 mutated adenocarcinoma of the lungs who received chemo-immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Falk, Markus, Willing, Eva, Schmidt, Stefanie, Schatz, Stefanie, Galster, Marco, Tiemann, Markus, Ficker, Joachim H., Brueckl, Wolfgang M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954890/
https://www.ncbi.nlm.nih.gov/pubmed/36826091
http://dx.doi.org/10.3390/curroncol30020130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954890/
https://www.ncbi.nlm.nih.gov/pubmed/36826091
http://dx.doi.org/10.3390/curroncol30020130

Ejemplares similares